462 results about "Kidney disease" patented technology

The invention belongs to the technical field of kidney histopathology and immunological evaluation, and particularly relates to a kidney pathology detection kit, a detection method and application, the detection kit comprises 37 rare metal element labeled monoclonal antibodies combined with antigens of in-situ tissue cells, and the detection method comprises the following steps: (1) collecting a sample to be detected, preparing a pre-dyed paraffin section; (2) mixing 37 monoclonal antibodies labeled by rare metal elements, and carrying out antibody staining on various antigen targets on the surfaces of cells in the in-situ tissue; (3) carrying out nucleus DNA staining on the stained tissue sample; and (4) detecting the stained tissue sample through an imaging mass spectrum flow system, and collecting original information data through laser spot firing. The method is an analysis method for fine grouping identification and relative quantification of structural cells, immune cells and pathological injury cells in the clinical nephropathy sample in-situ tissue. And auxiliary diagnosis information is provided for diagnosis, grading, treatment and prognosis detection of various clinical nephropathy.

The invention relates to a nephrotic patient health management method and system based on a neural network prediction model, and the method comprises the steps: obtaining the multi-dimensional health data of a target nephrotic patient at each stage, constructing a time sequence feature matrix to extract the change trend of the whole course of disease, and dividing the course of disease into a disease alleviation stage and a disease deterioration stage; analyzing the health data of the two stages to obtain an improvement factor and a deterioration factor; outputting a renal function state prediction result by using a neural network prediction model fusing an attention mechanism and a knowledge graph, and generating an initial health management scheme by combining the result, a preset health management rule base and patient preferences; and optimizing the initial scheme based on the improvement factor, the deterioration factor and a reinforcement learning algorithm to obtain an optimized health management scheme. Complete-cycle closed-loop management of data acquisition, trend analysis, factor identification, prediction and early warning, scheme generation and dynamic optimization of nephropathy patients is realized, and the accuracy and individuation level of nephropathy health management are improved.

Modified DDAH polypeptides and their uses thereof are provided. Exemplary embodiments provide DDAH polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and / or linkage to other biologically active molecules including other DDAH polypeptides, as well as PKEM. Additionally, use of said DDAH polypeptides for treatment of disease, such as heart failure or renal disease, is also provided.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention relates to the technical field of combination of medical treatment and computers, and discloses a kidney disease risk prediction method and system based on machine learning and a storage medium, and the method comprises the steps: collecting basic data of historical patients, carrying out the preprocessing of the basic data, and adding a label to serve as first learning data; constructing a plurality of first prediction models based on machine learning, training the first prediction models by using the first learning data, obtaining first prediction data, and integrating the first prediction data to generate a first data set; adding the first data set into the first learning data to form second learning data; constructing a plurality of second prediction models, training the second prediction models by using the second learning data, and selecting a target prediction model from the second prediction data; the basic data of the new patient is obtained and input into the target prediction model, the target prediction model outputs the prediction value of the kidney disease risk of the new patient, and the kidney disease risk can be predicted more accurately.

The invention relates to the technical field of microorganisms, in particular to compound probiotics capable of degrading indole and preventing or relieving nephropathy and application of the compound probiotics. The compound probiotics comprise bifidobacterium animalis subsp. Lactis YYS-J9 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.28185 and bifidobacterium longum subsp. Longum YYS-BSM8 with the preservation number of CGMCC NO.28611. The invention further discloses a preparation method of the compound probiotics. Compared with the use of a single YYS-J9 strain or YYS-BSM8 strain, the two strains have synergistic effects after being compounded, the viable count is remarkably increased after mixed culture, the inhibition effect on pathogenic enterobacteria and the adhesion to intestinal cells are remarkably enhanced, the degradation capacity on indole and oxalic acid is higher, the proliferation and phagocytic activity of macrophages is remarkably improved, and the application range of the YYS-J9 strain and the YYS-BSM8 strain is widened. And when being applied to food, health-care products or medicines, the exopolysaccharide can be used for effectively preventing or improving nephropathy and kidney stone, regulating intestinal health and improving intestinal immunity.

The invention discloses a detection kit and a detection system for IgA nephropathy, and belongs to the technical field of nephropathy detection.The kit comprises a plasma Gd-IgA1 detection reagent, a Gd-IgA1 fluorescent antibody, an IgA1 fluorescent antibody, a CD19 fluorescent antibody, a CD11c fluorescent antibody and a CD27 fluorescent antibody. The ratio of the first cell subset and the ratio of the second cell subset are detected through the detection kit, the IgA nephropathy is predicted / diagnosed, the detection kit has important guiding value for disease prognosis prediction and curative effect evaluation, and a new view is opened up for clinical management of the IgA nephropathy; the method is non-invasive clinical prediction and can realize non-invasive diagnosis.

The present disclosure provides engineered alpha klotho polypeptides and methods of their production and use. Soluble alpha klotho polypeptides disclosed herein comprise an alpha klotho moiety having one or more mutations for enhancing activity, production yield, and / or stability relative to human alpha klotho. The disclosure further provides pharmaceutical compositions comprising the engineered alpha klotho polypeptides, and methods of use of the engineered alpha klotho polypeptides in treatment methods, including treatment of age- related conditions and kidney disease. Also disclosed are nucleic acids encoding the engineered alpha klotho polypeptides, recombinant cells that express the engineered alpha klotho polypeptides, and methods of producing the engineered alpha klotho polypeptides.

The invention relates to thiophenyl derivatives and their use in the treatment and prophylaxis of diseases alleviated by APOL1 inhibition, such as an APOL1 mediated kidney disease, and to compositions containing said derivatives and processes for their preparation.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

Provided herein are compounds of formula (I'): or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein n,p, R1a, R1b, R1c, R1d, R2, R3, R4, L1, L2, L3, X1, X2, X3, X4, and X5 are as defined herein. Also provided are methods of preparing compounds of formula (I'), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition, such as kidney disease or diabetic retinopathy, in an individual.

The invention discloses a pet prescription wet food with a long-acting fresh-keeping function and a preparation method of the pet prescription wet food, and relates to the technical field of preparation of pet food. Comprising 40-60% of a meat raw material, 5-15% of dietary fibers, 0.5-2% of a vitamin premix, 0.3-1.5% of a mineral pre-coagulated material, 0.1-2% of a probiotic compound, 0.05-0.2% of a natural antioxidant, and the balance of water, hydrolyzed chicken, the natural antioxidant and a compound additive. According to the preparation method, a staged gradient sterilization process is combined with three-layer composite packaging and low-temperature plasma treatment, the unopened shelf life is prolonged to 24 months, which is far better than that of a traditional process, and the activity of thermosensitive components is guaranteed by adopting a nano-liposome embedding technology and sodium alginate-chitosan embedded probiotics, so that the preparation method is simple and convenient to operate. The protein digestibility is improved to 92% through low-molecular hydrolyzed protein, and the requirements of pets with kidney diseases are met.

The invention relates to the technical field of medical care informatics, in particular to a nephropathy medication interaction risk screening system which comprises a data acquisition unit, an SOC chip processing and analysis unit, a risk early warning unit and a man-machine interaction and communication unit. Through multi-source data access, dynamic weight scheduling and Kalman filtering fusion correction, accurate and on-demand acquisition of nephropathy core indexes is realized, and real-time intelligent discrimination of personalized medication risks is realized by relying on knowledge base support, adaptive path adjustment and a safe atomization updating mechanism, so that the risk of the nephropathy is accurately determined. Therefore, the problems that traditional system data acquisition lacks specialized pertinence, risk assessment personalization is insufficient, and model updating is lagged are effectively solved, and the accuracy and timeliness of nephropathy medication interaction risk screening are remarkably improved.

Described herein are antisense oligonucleotides, vectors, and related compositions and methods for increasing expression of PKD1 mRNA and Polycystin 1 protein and uses thereof for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor current and convert the sensor current generated by the continuous analyte sensor into digital signals, a processor configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.

Provided herein are compounds of formula (I'): or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein X1, X2, X3, X4, R1, R2, Y1, Y2, Y3, m,p, r, s, t, and ring A are as defined herein. Also provided are methods of preparing compounds of formula (I), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. Also provided are methods of inhibiting AP0L1 and methods of treating an AP0L1 -mediated disease, disorder, or condition, such as kidney disease or diabetic retinopathy, in an individual.

The invention relates to the technical field of image recognition, and discloses an image feature recognition method and system applied to the early stage of kidney diseases. According to the method, the features in the original ultrasonic image are extracted in parallel, and the micro texture change and the macroscopic form information shown in the abnormal area can be captured respectively, so that the limitation of a traditional single-scale feature extraction method in coping with diffusive and weak-saliency image features is overcome; the local texture feature map and the global structure feature map are analyzed, quantization and positioning of weak texture changes are achieved, priori knowledge is converted into objective indexes, pixel-level fusion is carried out on a texture abnormal map and a region importance weight map, and through the knowledge-guided and data-driven deep fusion method, the deep fusion of the texture abnormal map and the region importance weight map is achieved. It is ensured that the finally recognized abnormal area is not only a statistical outlier but also conforms to importance distribution of an image structure, and high-precision automatic recognition of weak and diffuse features in the kidney medical image is facilitated.

In an illustrative embodiment, systems and methods for treatment of nerves present in a wall of a human renal pelvis are described. One system uses a sheath to access a position in or near the renal pelvis via the urinary tract. An effector inserted through the sheath has an uncooled distal region formed with a superelastic wire that supports at least four non-insulated, preferably spherical electrodes distributed along the distal region. The distal region expands within the renal pelvis, and vacuum applied through the sheath at least partially evacuates the renal pelvis to draw opposing walls of the renal pelvis inwards and compress the distal region somewhat from its expanded form, placing the electrodes in intimate contact with different points along the renal pelvic wall. Energy is applied to the electrodes to create discrete lesions at the points of contact of the electrodes.

Described herein are methods for treatment of kidney disease, comprising administering to a patient in need thereof a cell-derived product to the perirenal adipose tissue (PRAT) of the patient. Optionally, the cell derived product is a plurality of mesenchymal stromal cells. Other diseases may be treated using this method including: a disease of the liver, cardiovascular disease, inflammatory disease, fibrotic disease, autoimmune disease, and disease of a visceral organ.

The invention relates to the technical field of abnormal process link prediction, in particular to a sample information tracing method for a kidney disease biological sample library. The method comprises the following steps: acquiring an abnormal kidney disease biological sample circulation process and constructing an FP tree; for any support degree threshold value in a preset support degree threshold value set, processing the FP tree through the support degree threshold value to obtain a maximum frequent item set; obtaining the reference weight of the maximum frequent item set based on the value and depth of each node of the path corresponding to the maximum frequent item set in the FP tree, and further obtaining the reasonable degree of the support degree threshold; and obtaining an optimal support degree threshold based on the reasonable degree, and predicting an abnormal process link of the kidney disease biological sample according to the optimal support degree threshold. According to the method, the optimal support degree threshold is obtained, so that the circulation process which easily causes the abnormality of the kidney disease biological sample is accurately predicted, the abnormal risk is processed and avoided in time, and the abnormal phenomenon of the kidney disease biological sample is effectively reduced.

The invention discloses a potential nephropathy prediction electronic nose system and method based on machine learning, and belongs to the technical field of medical detection. According to the system, ammonia concentration and temperature and humidity parameters in exhaled air of a human body are collected through a multi-mode sensor module, baseline calibration, flow velocity compensation and noise filtering are carried out in combination with a data preprocessing module, and a standardized characteristic matrix is generated. The machine learning prediction model adopts a Bayesian deep learning or integrated learning algorithm, inputs an ammonia concentration peak value, an integral area and temperature and humidity parameters, outputs a nephropathy risk probability and stage prediction, and quantifies key influence factors through an SHAP value (for example, a high-risk alarm is triggered when an ammonia concentration contribution degree is greater than or equal to 60%). The system is equipped with a real-time GUI interaction interface, dynamically displays a risk thermodynamic diagram and multi-dimensional data overlay analysis, and supports clinicians to feed back and correct. And the data iteration module realizes continuous optimization of the model through an encrypted cloud storage and incremental learning framework (Online SGD). A heterogeneous sensor array (such as a Fe2Mo3O8 / MoO2 (at) MoS2 composite material) and a dynamic temperature and humidity compensation technology are adopted, so that the detection stability is remarkably improved, and the clinical misdiagnosis rate is reduced. The system can be integrated in a portable device or a hospital system, is suitable for community screening, emergency triage and remote medical scenes, and has the advantages of noninvasive, high-precision and cross-mechanism collaborative diagnosis.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

The present disclosure provides a method and an apparatus for predicting a progression trajectory from acute kidney injury (AKI) to a kidney disease. The method includes the following steps: receiving a first set of features of a particular acute kidney injury (AKI) patient; selecting a second set of features from the first set of features using a preset algorithm; and predicting, using a first machine-learning model, a progression trajectory of a kidney disease of the particular AKI patient based on the second set of features.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.

The invention relates to a construction method, an evaluation method and application of an inflammatory nephropathy animal model, and relates to the technical field of nephropathy animal model construction. The construction method comprises the steps that a CRIPSR / Cas9 system is adopted to shear a first targeting site on an Smu region of a mouse immune globulin gene, and a second targeting site on an Sgamma2c region of the mouse immune globulin gene is sheared, so that a base sequence between the first targeting site and the second targeting site is knocked out, and the inflammatory nephropathy animal model is obtained. The application comprises an application of the inflammatory nephropathy animal model constructed by the construction method in screening drugs for treating inflammatory nephropathy and an application in researching a molecular mechanism of occurrence and development of inflammatory nephropathy.